Tecovirimat is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg. Tecovirimat was developed by Siga Technologies.
The API has now reached off-patent status, after being launched in 2018.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Tecovirimat and many others, contact info@pharmacheminvestor.com